Stocks and Investing Stocks and Investing
Mon, December 5, 2022
Sun, December 4, 2022
Fri, December 2, 2022
Thu, December 1, 2022
Wed, November 30, 2022

Mayank Mamtani Maintained (ARWR) at Strong Buy with Decreased Target to $59 on, Nov 30th, 2022


Published on 2024-10-28 00:22:35 - WOPRAI, Mayank Mamtani
  Print publication without navigation


Mayank Mamtani of B. Riley Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Decreased Target from $65 to $59 on, Nov 30th, 2022.

Mayank has made no other calls on ARWR in the last 4 months.



There are 5 other peers that have a rating on ARWR. Out of the 5 peers that are also analyzing ARWR, 2 agree with Mayank's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Galler of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Tuesday, November 29th, 2022
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $31 on, Tuesday, November 29th, 2022


These are the ratings of the 3 analyists that currently disagree with Mayank


  • Maury Raycroft of "Jefferies" Maintained at Strong Buy with Decreased Target to $75 on, Tuesday, November 29th, 2022
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $64 on, Thursday, November 10th, 2022
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $65 on, Monday, August 8th, 2022